Trial record 14 of 38 for:    " August 25, 2010":" September 24, 2010"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]

A Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

This study has been completed.
Sponsor:
Collaborator:
GlaxoSmithKline
Information provided by:
ViiV Healthcare
ClinicalTrials.gov Identifier:
NCT01209117
First received: September 17, 2010
Last updated: September 8, 2011
Last verified: September 2011
  Purpose

This is a single-center, randomized, two part, open-label, crossover study in healthy adult subjects to assess the oral bioavailability of three GSK2248761 Wet Bead Milled (WBM) tablet formulations manufactured by three different processes relative to the GSK2248761 WBM capsule formulation (Part A) and the effect of a moderate-fat meal on the bioavailability of the selected WBM tablet formulation (Part B).


Condition Intervention Phase
Infections, Human Immunodeficiency Virus and Herpesviridae
Infection, Human Immunodeficiency Virus
Drug: GSK2248761 WBM Capsule
Drug: GSK2248761 WBM Tablet Formulation 1
Drug: GSK2248761 WBM Tablet Formulation 2
Drug: GSK2248761 WBM Tablet Formulation 3
Drug: GSK2248761 WBM Tablet
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Bio-availability Study
Intervention Model: Crossover Assignment
Masking: Open Label
Official Title: A Single-center, Randomized, Open-label, Crossover Study to Assess the Relative Bioavailability of Tablet Formulations of GSK2248761 in Healthy Adult Subjects. SGN114435

Resource links provided by NLM:


Further study details as provided by ViiV Healthcare:

Primary Outcome Measures:
  • Plasma GSK2248761 Area under the concentration-time curve from time zero (pre-dose) extrapolated to infinite time (AUC(0-infinity)) [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
  • Plasma GSK2248761 Area under the concentration-time curve over the dosing interval (AUC (0 - t)) [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
  • Plasma GSK2248761 observed concentration 24 hours after dose (C24) [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
  • Plasma GSK2248761 Maximum observed concentration (Cmax) [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Safety and tolerability parameters, including adverse events [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
  • concurrent medication [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
  • Clinical laboratory screens [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
  • Electrocardiograms (ECG) [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
  • Vital sign assessments (systolic and diastolic blood pressure and pulse) [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
  • Plasma GSK2248761 terminal phase half life (t½) [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
  • Plasma GSK2248761 Lag time before observation of drug concentrations (tlag) [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
  • Plasma GSK2248761 Time of occurrence of Cmax (tmax) [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
  • Plasma GSK2248761 Percentage of AUC(0-infinity) obtained by extrapolation (%AUCex) [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
  • Plasma GSK2248761 Time of last quantifiable concentration (tlast) [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]
  • Plasma GSK2248761 Apparent clearance following oral dosing (CL/F) [ Time Frame: 5 weeks ] [ Designated as safety issue: No ]

Enrollment: 24
Study Start Date: September 2010
Study Completion Date: January 2011
Primary Completion Date: January 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Periods 1 - 4
Subjects will be randomized in a cross over fashion to receive the GSK2248761 WBM capsule formulation or one of three WBM tablet formulations in one of four sequences.
Drug: GSK2248761 WBM Capsule
200 mg GSK2248761 WBM capsule (reference) 2 X100mg
Drug: GSK2248761 WBM Tablet Formulation 1
GSK2248761 WBM Tablet 200mg manufacturing process 1
Drug: GSK2248761 WBM Tablet Formulation 2
GSK2248761 WBM Tablet 200mg manufacturing process 2
Drug: GSK2248761 WBM Tablet Formulation 3
GSK2248761 WBM Tablet 200mg manufacturing process 3
Experimental: Period 5
Subjects in Part B will receive a formulation of GSK2248761 200mg WBM Tablet chosen from Periods 1 - 4 in part A in the fed state (moderate fat meal).
Drug: GSK2248761 WBM Tablet
GSK2248761 WBM tablet 200mg manufacturing process 1, 2, or 3 chosen from Period 1 - 4

Detailed Description:

ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of updating systems to reflect the change in sponsorship

  Eligibility

Ages Eligible for Study:   18 Years to 50 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, vital signs, laboratory tests, and ECGs. A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the GSK Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures.
  • Male or female between 18 and 50 years of age inclusive, at the time of signing the informed consent.
  • A female subject is eligible to participate if she is of non-childbearing potential (i.e., physiologically incapable of becoming pregnant) including any female who: Is pre-menopausal with a documented bilateral tubal ligation, bilateral oophorectomy (removal of the ovaries) or hysterectomy, or Is post-menopausal defined as 12 months of spontaneous amenorrhea.
  • Male subjects must agree to use one of the contraception methods listed in the protocol. This criterion must be followed from the time of the first dose of study medication until the follow-up visit.
  • Body weight greater than or equal to 50 kilograms (kg) for men and greater than or equal to 45 kg for women and body mass index (BMI) within the range 18.5-31.0 kilograms per meters squared (inclusive).
  • Capable of giving written informed consent, which includes compliance with the requirements and restrictions listed in the consent form

Exclusion Criteria:

  • As a result of the medical interview, physical examination, or screening investigations, the Investigator considers the subject unfit for the study.
  • The subject has a positive pre-study drug/alcohol screen. A minimum list of drugs that will be screened for include amphetamines, barbiturates, cocaine, opiates, cannabinoids and benzodiazepines.
  • Unwilling to refrain from the use of illicit drugs and adhere to other protocol-stated restrictions while participating in the study.
  • History of regular alcohol consumption within 6 months of the study defined as: An average weekly intake of greater than14 drinks/week for men or greater than 7 drinks/week for women.
  • Unwilling to abstain from alcohol for 48 hours prior to the start of dosing until collection of the final pharmacokinetic sample during each treatment period.
  • History or regular use of tobacco- or nicotine-containing products within 3 months prior to screening.
  • History/evidence of symptomatic arrhythmia, angina/ischemia, coronary artery bypass grafting surgery or percutaneous transluminal coronary angioplasty or any clinically significant cardiac disease.
  • History/evidence of clinically significant pulmonary disease.
  • Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones).
  • Subjects with a pre-existing condition interfering with normal gastrointestinal anatomy or motility, hepatic and/or renal function, that could interfere with the absorption, metabolism, and/or excretion of the study drugs. Subjects with a history of cholecystectomy should be excluded.
  • The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product (whichever is longer).
  • Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and GSK Medical Monitor the medication will not interfere with the study procedures or compromise subject safety.
  • History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or GSK Medical Monitor, contraindicates their participation. In addition, if heparin is used during PK sampling, subjects with a history of sensitivity to heparin or heparin-induced thrombocytopenia should not be enrolled.
  • Where participation in the study would result in donation of blood or blood products in excess of 500 milliliters (mL) within a 56 day period.

Note: this does not include plasma donation.

  • A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening.
  • A positive test for HIV antibody.
  • aspartate aminotransferase (AST), alanine aminotransferase (ALT) , alkaline phosphatase and bilirubin greater than or equal to 1.5 times the Upper limit of normal (isolated bilirubin >1.5 times the upper limit of normal is acceptable if bilirubin is fractionated and direct bilirubin less than 35%).
  • Pregnant females as determined by positive serum pregnancy test at screening or prior to dosing.
  • Lactating females.
  • The subject's systolic blood pressure is outside the range of 90-140 millimeters of mercury, or diastolic blood pressure is outside the range of 45-90millimeters of mercury or heart rate is outside the range of 50-100beats per minute for female subjects or 45-100 beats per minute for male subjects at Screening and predose Day 1.
  • Cardiac conduction abnormalities denoted by any of the following on a single 12-lead ECG at screening or predose Day 1.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01209117

Locations
United States, New York
GSK Investigational Site
Buffalo, New York, United States, 14202
Sponsors and Collaborators
ViiV Healthcare
GlaxoSmithKline
Investigators
Study Director: GSK Clinical Trials ViiV Healthcare
  More Information

No publications provided

Responsible Party: Cheri Hudson; Clinical Disclosure Advisor, GSK Clinical Disclosure
ClinicalTrials.gov Identifier: NCT01209117     History of Changes
Other Study ID Numbers: 114435
Study First Received: September 17, 2010
Last Updated: September 8, 2011
Health Authority: United States: Food and Drug Administration

Keywords provided by ViiV Healthcare:
formulation
bioavailability
pharmacokinetics
GSK2248761

Additional relevant MeSH terms:
Acquired Immunodeficiency Syndrome
HIV Infections
Immunologic Deficiency Syndromes
Virus Diseases
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Slow Virus Diseases
Immune System Diseases

ClinicalTrials.gov processed this record on July 28, 2014